Niagen Bioscience (NAGE) Net Cash Flow (2011 - 2026)

Niagen Bioscience (NAGE) has 14 years of Net Cash Flow data on file, last reported at $1.8 million in Q1 2026.

• Net Cash Flow for Q1 2026 came in at $1.8 million, down 83.93% year-over-year; the trailing twelve-month figure through Mar 2026 was $10.9 million (down 61.02% YoY), and the FY2025 annual result was $20.1 million, up 16.11% from the prior year.
• Net Cash Flow climbed to $1.8 million in Q1 2026 per NAGE's latest filing, from $498000.0 in the prior quarter.
• Over five years, Net Cash Flow peaked at $12.3 million in Q4 2024 and troughed at -$7.2 million in Q1 2022.
• A 5-year average of $2.3 million and a median of $1.8 million in 2026 frame the typical range for Net Cash Flow.
• The sharpest annual moves came in 2022 and 2025: Net Cash Flow slumped 125.81% in 2022, then soared 4465.0% in 2025.
• A 5-year view of Net Cash Flow shows it stood at $7.2 million in 2022, then plunged by 92.31% to $552000.0 in 2023, then soared by 2121.38% to $12.3 million in 2024, then plunged by 95.94% to $498000.0 in 2025, then surged by 253.61% to $1.8 million in 2026.
• Business Quant data shows NAGE's Net Cash Flow at $1.8 million in Q1 2026, $498000.0 in Q4 2025, and $3.8 million in Q3 2025.